| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| OKUR - OKUR | SELL | -21 @ USD 3.01997 | USD -63 | The ETF sold 21 shares of OKUR on 2025-12-16. The shares were previously bought for an average price of USD 5.56734. The OKUR shares were sold for -45.8% lower than average price of previous purchases. This resulted in an overall loss of USD 53 The average price that the ETF previously sold OKUR share for is USD 4.54832 which is higher than the selling price of USD 3.01997 on 2025-12-16. |
| PLRX - Pliant Therapeutics Inc | SELL | -100 @ USD 1.25001 | USD -125 | The ETF sold 100 shares of PLRX on 2025-12-16. The shares were previously bought for an average price of USD 1.47912. The Pliant Therapeutics Inc shares were sold for -15.5% lower than average price of previous purchases. This resulted in an overall loss of USD 23 The average price that the ETF previously sold PLRX share for is USD 6.378 which is higher than the selling price of USD 1.25001 on 2025-12-16. |
| STRO - Sutro Biopharma | SELL | -13 @ USD 9.80997 | USD -128 | The ETF sold 13 shares of STRO on 2025-12-16. The shares were previously bought for an average price of USD 1.03176. The Sutro Biopharma shares were sold for 850.8% higher than average price of previous purchases. This sale made a profit of USD 114 The average price that the ETF previously sold STRO share for is USD 7.54319 so the ETF has sold 13 shares on 2025-12-16 at a higher price than the previous selling average. |
| MGNX - MacroGenics Inc | SELL | -107 @ USD 1.35001 | USD -144 | The ETF sold 107 shares of MGNX on 2025-12-16. The shares were previously bought for an average price of USD 1.52908. The MacroGenics Inc shares were sold for -11.7% lower than average price of previous purchases. This resulted in an overall loss of USD 19 The average price that the ETF previously sold MGNX share for is USD 2.1731 which is higher than the selling price of USD 1.35001 on 2025-12-16. |
| BMEA - Biomea Fusion Inc | SELL | -120 @ USD 1.37 | USD -164 | The ETF sold 120 shares of BMEA on 2025-12-16. The shares were previously bought for an average price of USD 1.51319. The Biomea Fusion Inc shares were sold for -9.5% lower than average price of previous purchases. This resulted in an overall loss of USD 17 The average price that the ETF previously sold BMEA share for is USD 3.01086 which is higher than the selling price of USD 1.37 on 2025-12-16. |
| FATE - Fate Therapeutics Inc | SELL | -190 @ USD 1.09 | USD -207 | The ETF sold 190 shares of FATE on 2025-12-16. The shares were previously bought for an average price of USD 1.1465. The Fate Therapeutics Inc shares were sold for -4.9% lower than average price of previous purchases. This resulted in an overall loss of USD 11 The average price that the ETF previously sold FATE share for is USD 1.02602 so the ETF has sold 190 shares on 2025-12-16 at a higher price than the previous selling average. |
| MRSN - Mersana Therapeutics Inc | SELL | -8 @ USD 29.0449 | USD -232 | The ETF sold 8 shares of MRSN on 2025-12-16. The shares were previously bought for an average price of USD 1.31897. The Mersana Therapeutics Inc shares were sold for 2,102.1% higher than average price of previous purchases. This sale made a profit of USD 222 The average price that the ETF previously sold MRSN share for is USD 5.96738 so the ETF has sold 8 shares on 2025-12-16 at a higher price than the previous selling average. |
| ALEC - Alector Inc | SELL | -184 @ USD 1.39 | USD -256 | The ETF sold 184 shares of ALEC on 2025-12-16. The shares were previously bought for an average price of USD 1.70509. The Alector Inc shares were sold for -18.5% lower than average price of previous purchases. This resulted in an overall loss of USD 58 The average price that the ETF previously sold ALEC share for is USD 1.92012 which is higher than the selling price of USD 1.39 on 2025-12-16. |
| MXCT - MaxCyte Inc | SELL | -185 @ USD 1.47 | USD -272 | The ETF sold 185 shares of MXCT on 2025-12-16. The shares were previously bought for an average price of USD 1.99956. The MaxCyte Inc shares were sold for -26.5% lower than average price of previous purchases. This resulted in an overall loss of USD 98 The average price that the ETF previously sold MXCT share for is USD 2.77307 which is higher than the selling price of USD 1.47 on 2025-12-16. |
| HUMA - Humacyte Inc | SELL | -283 @ USD 1.12 | USD -317 | The ETF sold 283 shares of HUMA on 2025-12-16. The shares were previously bought for an average price of USD 1.98857. The Humacyte Inc shares were sold for -43.7% lower than average price of previous purchases. This resulted in an overall loss of USD 246 The average price that the ETF previously sold HUMA share for is USD 2.75639 which is higher than the selling price of USD 1.12 on 2025-12-16. |
| ARCT - Arcturus Therapeutics Holdings Inc | SELL | -49 @ USD 7.13001 | USD -349 | The ETF sold 49 shares of ARCT on 2025-12-16. The shares were previously bought for an average price of USD 12.4562. The Arcturus Therapeutics Holdings Inc shares were sold for -42.8% lower than average price of previous purchases. This resulted in an overall loss of USD 261 The average price that the ETF previously sold ARCT share for is USD 14.328 which is higher than the selling price of USD 7.13001 on 2025-12-16. |
| VYGR - Voyager Therapeutics Inc | SELL | -89 @ USD 4.41999 | USD -393 | The ETF sold 89 shares of VYGR on 2025-12-16. The shares were previously bought for an average price of USD 3.93356. The Voyager Therapeutics Inc shares were sold for 12.4% higher than average price of previous purchases. This sale made a profit of USD 43 The average price that the ETF previously sold VYGR share for is USD 4.69635 which is higher than the selling price of USD 4.41999 on 2025-12-16. |
| EDIT - Editas Medicine Inc | SELL | -166 @ USD 2.51 | USD -417 | The ETF sold 166 shares of EDIT on 2025-12-16. The shares were previously bought for an average price of USD 2.61551. The Editas Medicine Inc shares were sold for -4.0% lower than average price of previous purchases. This resulted in an overall loss of USD 18 The average price that the ETF previously sold EDIT share for is USD 2.01525 so the ETF has sold 166 shares on 2025-12-16 at a higher price than the previous selling average. |
| OABI - OmniAb Inc. | SELL | -215 @ USD 2.05 | USD -441 | The ETF sold 215 shares of OABI on 2025-12-16. The shares were previously bought for an average price of USD 1.88823. The OmniAb Inc. shares were sold for 8.6% higher than average price of previous purchases. This sale made a profit of USD 35 The average price that the ETF previously sold OABI share for is USD 2.73713 which is higher than the selling price of USD 2.05 on 2025-12-16. |
| AVIR - Atea Pharmaceuticals Inc | SELL | -145 @ USD 3.22 | USD -467 | The ETF sold 145 shares of AVIR on 2025-12-16. The shares were previously bought for an average price of USD 3.25167. The Atea Pharmaceuticals Inc shares were sold for -1.0% lower than average price of previous purchases. This resulted in an overall loss of USD 5 The average price that the ETF previously sold AVIR share for is USD 3.14486 so the ETF has sold 145 shares on 2025-12-16 at a higher price than the previous selling average. |
| ACIU - AC Immune Ltd | SELL | -174 @ USD 3.29 | USD -572 | The ETF sold 174 shares of ACIU on 2025-12-16. The shares were previously bought for an average price of USD 2.56758. The AC Immune Ltd shares were sold for 28.1% higher than average price of previous purchases. This sale made a profit of USD 126 The average price that the ETF previously sold ACIU share for is USD 2.34897 so the ETF has sold 174 shares on 2025-12-16 at a higher price than the previous selling average. |
| ALLO - Allogene Therapeutics Inc | SELL | -381 @ USD 1.54 | USD -587 | The ETF sold 381 shares of ALLO on 2025-12-16. The shares were previously bought for an average price of USD 1.34689. The Allogene Therapeutics Inc shares were sold for 14.3% higher than average price of previous purchases. This sale made a profit of USD 74 The average price that the ETF previously sold ALLO share for is USD 1.81785 which is higher than the selling price of USD 1.54 on 2025-12-16. |
| BCYC - Bicycle Therapeutics Ltd | SELL | -81 @ USD 7.30999 | USD -592 | The ETF sold 81 shares of BCYC on 2025-12-16. The shares were previously bought for an average price of USD 8.15555. The Bicycle Therapeutics Ltd shares were sold for -10.4% lower than average price of previous purchases. This resulted in an overall loss of USD 68 The average price that the ETF previously sold BCYC share for is USD 10.5159 which is higher than the selling price of USD 7.30999 on 2025-12-16. |
| AVXL - Anavex Life Sciences Corp | SELL | -149 @ USD 4.02 | USD -599 | The ETF sold 149 shares of AVXL on 2025-12-16. The shares were previously bought for an average price of USD 8.07409. The Anavex Life Sciences Corp shares were sold for -50.2% lower than average price of previous purchases. This resulted in an overall loss of USD 604 The average price that the ETF previously sold AVXL share for is USD 9.25255 which is higher than the selling price of USD 4.02 on 2025-12-16. |
| AUTL - Autolus Therapeutics Ltd | SELL | -378 @ USD 1.6 | USD -605 | The ETF sold 378 shares of AUTL on 2025-12-16. The shares were previously bought for an average price of USD 1.74199. The Autolus Therapeutics Ltd shares were sold for -8.2% lower than average price of previous purchases. This resulted in an overall loss of USD 54 The average price that the ETF previously sold AUTL share for is USD 2.08126 which is higher than the selling price of USD 1.6 on 2025-12-16. |
| RCKT - Rocket Pharmaceuticals Inc | SELL | -185 @ USD 3.43001 | USD -635 | The ETF sold 185 shares of RCKT on 2025-12-16. The shares were previously bought for an average price of USD 4.6478. The Rocket Pharmaceuticals Inc shares were sold for -26.2% lower than average price of previous purchases. This resulted in an overall loss of USD 225 The average price that the ETF previously sold RCKT share for is USD 8.54914 which is higher than the selling price of USD 3.43001 on 2025-12-16. |
| HCM - HUTCHMED China Ltd | SELL | -55 @ USD 13.19 | USD -725 | The ETF sold 55 shares of HCM on 2025-12-16. The shares were previously bought for an average price of USD 15.1543. The HUTCHMED China Ltd shares were sold for -13.0% lower than average price of previous purchases. This resulted in an overall loss of USD 108 The average price that the ETF previously sold HCM share for is USD 15.1096 which is higher than the selling price of USD 13.19 on 2025-12-16. |
| HCM - Hitachi Construction Machinery Co. Ltd | SELL | -55 @ USD 13.19 | USD -725 | The ETF sold 55 shares of HCM on 2025-12-16. The shares were previously bought for an average price of USD 15.1543. The Hitachi Construction Machinery Co. Ltd shares were sold for -13.0% lower than average price of previous purchases. This resulted in an overall loss of USD 108 The average price that the ETF previously sold HCM share for is USD 15.1096 which is higher than the selling price of USD 13.19 on 2025-12-16. |
| VNDA - Vanda Pharmaceuticals Inc | SELL | -110 @ USD 6.65001 | USD -732 | The ETF sold 110 shares of VNDA on 2025-12-16. The shares were previously bought for an average price of USD 4.93606. The Vanda Pharmaceuticals Inc shares were sold for 34.7% higher than average price of previous purchases. This sale made a profit of USD 189 The average price that the ETF previously sold VNDA share for is USD 4.75419 so the ETF has sold 110 shares on 2025-12-16 at a higher price than the previous selling average. |
| ALT - Altitude Group Plc | SELL | -146 @ USD 5.03 | USD -734 | The ETF sold 146 shares of ALT on 2025-12-16. The shares were previously bought for an average price of USD 5.14417. The Altitude Group Plc shares were sold for -2.2% lower than average price of previous purchases. This resulted in an overall loss of USD 17 The average price that the ETF previously sold ALT share for is USD 4.69216 so the ETF has sold 146 shares on 2025-12-16 at a higher price than the previous selling average. |
| SIGA - SIGA Technologies Inc | SELL | -121 @ USD 6.28 | USD -760 | The ETF sold 121 shares of SIGA on 2025-12-16. The shares were previously bought for an average price of USD 6.6331. The SIGA Technologies Inc shares were sold for -5.3% lower than average price of previous purchases. This resulted in an overall loss of USD 43 The average price that the ETF previously sold SIGA share for is USD 6.64579 which is higher than the selling price of USD 6.28 on 2025-12-16. |
| LXRX - Lexicon Pharmaceuticals Inc | SELL | -651 @ USD 1.2 | USD -781 | The ETF sold 651 shares of LXRX on 2025-12-16. The shares were previously bought for an average price of USD 1.15741. The Lexicon Pharmaceuticals Inc shares were sold for 3.7% higher than average price of previous purchases. This sale made a profit of USD 28 The average price that the ETF previously sold LXRX share for is USD 0.766999 so the ETF has sold 651 shares on 2025-12-16 at a higher price than the previous selling average. |
| TRDA - Entrada Therapeutics Inc | SELL | -70 @ USD 11.37 | USD -796 | The ETF sold 70 shares of TRDA on 2025-12-16. The shares were previously bought for an average price of USD 8.23347. The Entrada Therapeutics Inc shares were sold for 38.1% higher than average price of previous purchases. This sale made a profit of USD 220 The average price that the ETF previously sold TRDA share for is USD 8.40738 so the ETF has sold 70 shares on 2025-12-16 at a higher price than the previous selling average. |
| GLPG - Galapagos NV ADR | SELL | -26 @ USD 31.08 | USD -808 | The ETF sold 26 shares of GLPG on 2025-12-16. The shares were previously bought for an average price of USD 29.7426. The Galapagos NV ADR shares were sold for 4.5% higher than average price of previous purchases. This sale made a profit of USD 35 The average price that the ETF previously sold GLPG share for is USD 27.2798 so the ETF has sold 26 shares on 2025-12-16 at a higher price than the previous selling average. |
| GLPG - Galapagos N.V. | SELL | -26 @ USD 31.08 | USD -808 | The ETF sold 26 shares of GLPG on 2025-12-16. The shares were previously bought for an average price of USD 29.7426. The Galapagos N.V. shares were sold for 4.5% higher than average price of previous purchases. This sale made a profit of USD 35 The average price that the ETF previously sold GLPG share for is USD 27.2798 so the ETF has sold 26 shares on 2025-12-16 at a higher price than the previous selling average. |
| EOLS - Evolus Inc | SELL | -120 @ USD 7.22001 | USD -866 | The ETF sold 120 shares of EOLS on 2025-12-16. The shares were previously bought for an average price of USD 8.56985. The Evolus Inc shares were sold for -15.8% lower than average price of previous purchases. This resulted in an overall loss of USD 162 The average price that the ETF previously sold EOLS share for is USD 10.8109 which is higher than the selling price of USD 7.22001 on 2025-12-16. |
| PRTA - Prothena Corporation plc | SELL | -94 @ USD 9.75 | USD -917 | The ETF sold 94 shares of PRTA on 2025-12-16. The shares were previously bought for an average price of USD 9.45542. The Prothena Corporation plc shares were sold for 3.1% higher than average price of previous purchases. This sale made a profit of USD 28 The average price that the ETF previously sold PRTA share for is USD 12.3545 which is higher than the selling price of USD 9.75 on 2025-12-16. |
| MRVI - Maravai Lifesciences Holdings Inc | SELL | -267 @ USD 3.59 | USD -959 | The ETF sold 267 shares of MRVI on 2025-12-16. The shares were previously bought for an average price of USD 2.94024. The Maravai Lifesciences Holdings Inc shares were sold for 22.1% higher than average price of previous purchases. This sale made a profit of USD 173 The average price that the ETF previously sold MRVI share for is USD 3.70674 which is higher than the selling price of USD 3.59 on 2025-12-16. |
| FDMT - 4D Molecular Therapeutics Inc | SELL | -85 @ USD 11.52 | USD -979 | The ETF sold 85 shares of FDMT on 2025-12-16. The shares were previously bought for an average price of USD 7.76202. The 4D Molecular Therapeutics Inc shares were sold for 48.4% higher than average price of previous purchases. This sale made a profit of USD 319 The average price that the ETF previously sold FDMT share for is USD 5.51432 so the ETF has sold 85 shares on 2025-12-16 at a higher price than the previous selling average. |
| LYEL - Lyell Immunopharma Inc | SELL | -32 @ USD 32.64 | USD -1,044 | The ETF sold 32 shares of LYEL on 2025-12-16. The shares were previously bought for an average price of USD 8.48496. The Lyell Immunopharma Inc shares were sold for 284.7% higher than average price of previous purchases. This sale made a profit of USD 773 The average price that the ETF previously sold LYEL share for is USD 6.64514 so the ETF has sold 32 shares on 2025-12-16 at a higher price than the previous selling average. |
| IRWD - Ironwood Pharmaceuticals Inc | SELL | -296 @ USD 3.54 | USD -1,048 | The ETF sold 296 shares of IRWD on 2025-12-16. The shares were previously bought for an average price of USD 2.34928. The Ironwood Pharmaceuticals Inc shares were sold for 50.7% higher than average price of previous purchases. This sale made a profit of USD 352 The average price that the ETF previously sold IRWD share for is USD 2.67647 so the ETF has sold 296 shares on 2025-12-16 at a higher price than the previous selling average. |
| CGEM - Cullinan Oncology LLC | SELL | -104 @ USD 10.22 | USD -1,063 | The ETF sold 104 shares of CGEM on 2025-12-16. The shares were previously bought for an average price of USD 8.57694. The Cullinan Oncology LLC shares were sold for 19.2% higher than average price of previous purchases. This sale made a profit of USD 171 The average price that the ETF previously sold CGEM share for is USD 10.0969 so the ETF has sold 104 shares on 2025-12-16 at a higher price than the previous selling average. |
| PACB - Pacific Biosciences of California | SELL | -538 @ USD 2.02 | USD -1,087 | The ETF sold 538 shares of PACB on 2025-12-16. The shares were previously bought for an average price of USD 1.69829. The Pacific Biosciences of California shares were sold for 18.9% higher than average price of previous purchases. This sale made a profit of USD 173 The average price that the ETF previously sold PACB share for is USD 1.44913 so the ETF has sold 538 shares on 2025-12-16 at a higher price than the previous selling average. |
| PRME - Prime Medicine, Inc. Common Stock | SELL | -296 @ USD 3.88 | USD -1,148 | The ETF sold 296 shares of PRME on 2025-12-16. The shares were previously bought for an average price of USD 4.34727. The Prime Medicine, Inc. Common Stock shares were sold for -10.7% lower than average price of previous purchases. This resulted in an overall loss of USD 138 The average price that the ETF previously sold PRME share for is USD 2.7746 so the ETF has sold 296 shares on 2025-12-16 at a higher price than the previous selling average. |
| MGTX - MeiraGTx Holdings PLC | SELL | -136 @ USD 8.6 | USD -1,170 | The ETF sold 136 shares of MGTX on 2025-12-16. The shares were previously bought for an average price of USD 7.4402. The MeiraGTx Holdings PLC shares were sold for 15.6% higher than average price of previous purchases. This sale made a profit of USD 158 The average price that the ETF previously sold MGTX share for is USD 6.96158 so the ETF has sold 136 shares on 2025-12-16 at a higher price than the previous selling average. |
| RGNX - Regenxbio Inc | SELL | -89 @ USD 14.11 | USD -1,256 | The ETF sold 89 shares of RGNX on 2025-12-16. The shares were previously bought for an average price of USD 10.0406. The Regenxbio Inc shares were sold for 40.5% higher than average price of previous purchases. This sale made a profit of USD 362 The average price that the ETF previously sold RGNX share for is USD 7.853 so the ETF has sold 89 shares on 2025-12-16 at a higher price than the previous selling average. |
| REPL - Replimune Group Inc | SELL | -135 @ USD 9.60999 | USD -1,297 | The ETF sold 135 shares of REPL on 2025-12-16. The shares were previously bought for an average price of USD 9.15336. The Replimune Group Inc shares were sold for 5.0% higher than average price of previous purchases. This sale made a profit of USD 62 The average price that the ETF previously sold REPL share for is USD 9.95984 which is higher than the selling price of USD 9.60999 on 2025-12-16. |
| PAHC - Phibro Animal Health Corporation | SELL | -33 @ USD 40.4 | USD -1,333 | The ETF sold 33 shares of PAHC on 2025-12-16. The shares were previously bought for an average price of USD 31.5119. The Phibro Animal Health Corporation shares were sold for 28.2% higher than average price of previous purchases. This sale made a profit of USD 293 The average price that the ETF previously sold PAHC share for is USD 25.7906 so the ETF has sold 33 shares on 2025-12-16 at a higher price than the previous selling average. |
| IOVA - Iovance Biotherapeutics Inc | SELL | -600 @ USD 2.25 | USD -1,350 | The ETF sold 600 shares of IOVA on 2025-12-16. The shares were previously bought for an average price of USD 2.3941. The Iovance Biotherapeutics Inc shares were sold for -6.0% lower than average price of previous purchases. This resulted in an overall loss of USD 86 The average price that the ETF previously sold IOVA share for is USD 4.95285 which is higher than the selling price of USD 2.25 on 2025-12-16. |
| ZLAB - Zai Lab Ltd | SELL | -80 @ USD 17 | USD -1,360 | The ETF sold 80 shares of ZLAB on 2025-12-16. The shares were previously bought for an average price of USD 31.0921. The Zai Lab Ltd shares were sold for -45.3% lower than average price of previous purchases. This resulted in an overall loss of USD 1,127 The average price that the ETF previously sold ZLAB share for is USD 31.0299 which is higher than the selling price of USD 17 on 2025-12-16. |
| DAWN - Day One Biopharmaceuticals Inc | SELL | -171 @ USD 8.25001 | USD -1,411 | The ETF sold 171 shares of DAWN on 2025-12-16. The shares were previously bought for an average price of USD 7.72272. The Day One Biopharmaceuticals Inc shares were sold for 6.8% higher than average price of previous purchases. This sale made a profit of USD 90 The average price that the ETF previously sold DAWN share for is USD 9.28559 which is higher than the selling price of USD 8.25001 on 2025-12-16. |
| GERN - Geron Corporation | SELL | -1,066 @ USD 1.34 | USD -1,428 | The ETF sold 1066 shares of GERN on 2025-12-16. The shares were previously bought for an average price of USD 1.43749. The Geron Corporation shares were sold for -6.8% lower than average price of previous purchases. This resulted in an overall loss of USD 104 The average price that the ETF previously sold GERN share for is USD 2.20237 which is higher than the selling price of USD 1.34 on 2025-12-16. |
| KALV - Kalvista Pharmaceuticals Inc | SELL | -90 @ USD 15.9 | USD -1,431 | The ETF sold 90 shares of KALV on 2025-12-16. The shares were previously bought for an average price of USD 13.5733. The Kalvista Pharmaceuticals Inc shares were sold for 17.1% higher than average price of previous purchases. This sale made a profit of USD 209 The average price that the ETF previously sold KALV share for is USD 11.9021 so the ETF has sold 90 shares on 2025-12-16 at a higher price than the previous selling average. |
| TBPH - Theravance Biopharma Inc | SELL | -84 @ USD 17.53 | USD -1,473 | The ETF sold 84 shares of TBPH on 2025-12-16. The shares were previously bought for an average price of USD 13.5517. The Theravance Biopharma Inc shares were sold for 29.4% higher than average price of previous purchases. This sale made a profit of USD 334 The average price that the ETF previously sold TBPH share for is USD 11.2016 so the ETF has sold 84 shares on 2025-12-16 at a higher price than the previous selling average. |
| JANX - Janux Therapeutics Inc | SELL | -101 @ USD 14.65 | USD -1,480 | The ETF sold 101 shares of JANX on 2025-12-16. The shares were previously bought for an average price of USD 26.2528. The Janux Therapeutics Inc shares were sold for -44.2% lower than average price of previous purchases. This resulted in an overall loss of USD 1,172 The average price that the ETF previously sold JANX share for is USD 36.3805 which is higher than the selling price of USD 14.65 on 2025-12-16. |
| ORIC - Oric Pharmaceuticals Inc | SELL | -163 @ USD 9.12 | USD -1,487 | The ETF sold 163 shares of ORIC on 2025-12-16. The shares were previously bought for an average price of USD 10.6475. The Oric Pharmaceuticals Inc shares were sold for -14.3% lower than average price of previous purchases. This resulted in an overall loss of USD 249 The average price that the ETF previously sold ORIC share for is USD 8.28638 so the ETF has sold 163 shares on 2025-12-16 at a higher price than the previous selling average. |
| VIR - Vir Biotechnology Inc | SELL | -232 @ USD 6.48 | USD -1,503 | The ETF sold 232 shares of VIR on 2025-12-16. The shares were previously bought for an average price of USD 5.92884. The Vir Biotechnology Inc shares were sold for 9.3% higher than average price of previous purchases. This sale made a profit of USD 128 The average price that the ETF previously sold VIR share for is USD 6.36721 so the ETF has sold 232 shares on 2025-12-16 at a higher price than the previous selling average. |
| VIR - Vidrala S.A | SELL | -232 @ USD 6.48 | USD -1,503 | The ETF sold 232 shares of VIR on 2025-12-16. The shares were previously bought for an average price of USD 5.92884. The Vidrala S.A shares were sold for 9.3% higher than average price of previous purchases. This sale made a profit of USD 128 The average price that the ETF previously sold VIR share for is USD 6.36721 so the ETF has sold 232 shares on 2025-12-16 at a higher price than the previous selling average. |
| ABUS - Arbutus Biopharma Corp | SELL | -328 @ USD 4.59 | USD -1,506 | The ETF sold 328 shares of ABUS on 2025-12-16. The shares were previously bought for an average price of USD 3.83964. The Arbutus Biopharma Corp shares were sold for 19.5% higher than average price of previous purchases. This sale made a profit of USD 246 The average price that the ETF previously sold ABUS share for is USD 3.36834 so the ETF has sold 328 shares on 2025-12-16 at a higher price than the previous selling average. |
| ARVN - Arvinas Inc | SELL | -130 @ USD 11.9 | USD -1,547 | The ETF sold 130 shares of ARVN on 2025-12-16. The shares were previously bought for an average price of USD 9.94644. The Arvinas Inc shares were sold for 19.6% higher than average price of previous purchases. This sale made a profit of USD 254 The average price that the ETF previously sold ARVN share for is USD 12.3822 which is higher than the selling price of USD 11.9 on 2025-12-16. |
| KROS - Keros Therapeutics Inc | SELL | -72 @ USD 21.53 | USD -1,550 | The ETF sold 72 shares of KROS on 2025-12-16. The shares were previously bought for an average price of USD 15.8434. The Keros Therapeutics Inc shares were sold for 35.9% higher than average price of previous purchases. This sale made a profit of USD 409 The average price that the ETF previously sold KROS share for is USD 19.8228 so the ETF has sold 72 shares on 2025-12-16 at a higher price than the previous selling average. |
| MNMD - Mind Medicine Inc | SELL | -130 @ USD 12.26 | USD -1,594 | The ETF sold 130 shares of MNMD on 2025-12-16. The shares were previously bought for an average price of USD 9.5334. The Mind Medicine Inc shares were sold for 28.6% higher than average price of previous purchases. This sale made a profit of USD 354 The average price that the ETF previously sold MNMD share for is USD 7.33423 so the ETF has sold 130 shares on 2025-12-16 at a higher price than the previous selling average. |
| KURA - Kura Oncology Inc | SELL | -152 @ USD 10.63 | USD -1,616 | The ETF sold 152 shares of KURA on 2025-12-16. The shares were previously bought for an average price of USD 8.28389. The Kura Oncology Inc shares were sold for 28.3% higher than average price of previous purchases. This sale made a profit of USD 357 The average price that the ETF previously sold KURA share for is USD 8.86816 so the ETF has sold 152 shares on 2025-12-16 at a higher price than the previous selling average. |
| NTLA - Intellia Therapeutics Inc | SELL | -182 @ USD 9.12 | USD -1,660 | The ETF sold 182 shares of NTLA on 2025-12-16. The shares were previously bought for an average price of USD 11.4968. The Intellia Therapeutics Inc shares were sold for -20.7% lower than average price of previous purchases. This resulted in an overall loss of USD 433 The average price that the ETF previously sold NTLA share for is USD 11.1253 which is higher than the selling price of USD 9.12 on 2025-12-16. |
| ELVN - Enliven Therapeutics Inc. | SELL | -99 @ USD 16.91 | USD -1,674 | The ETF sold 99 shares of ELVN on 2025-12-16. The shares were previously bought for an average price of USD 20.5559. The Enliven Therapeutics Inc. shares were sold for -17.7% lower than average price of previous purchases. This resulted in an overall loss of USD 361 The average price that the ETF previously sold ELVN share for is USD 21.3841 which is higher than the selling price of USD 16.91 on 2025-12-16. |
| TNGX - Tango Therapeutics Inc | SELL | -187 @ USD 8.96 | USD -1,676 | The ETF sold 187 shares of TNGX on 2025-12-16. The shares were previously bought for an average price of USD 7.2819. The Tango Therapeutics Inc shares were sold for 23.0% higher than average price of previous purchases. This sale made a profit of USD 314 The average price that the ETF previously sold TNGX share for is USD 3.63003 so the ETF has sold 187 shares on 2025-12-16 at a higher price than the previous selling average. |
| ABCL - Abcellera Biologics Inc | SELL | -502 @ USD 3.46 | USD -1,737 | The ETF sold 502 shares of ABCL on 2025-12-16. The shares were previously bought for an average price of USD 3.83934. The Abcellera Biologics Inc shares were sold for -9.9% lower than average price of previous purchases. This resulted in an overall loss of USD 190 The average price that the ETF previously sold ABCL share for is USD 3.19062 so the ETF has sold 502 shares on 2025-12-16 at a higher price than the previous selling average. |
| NVAX - Novavax Inc | SELL | -272 @ USD 6.54 | USD -1,779 | The ETF sold 272 shares of NVAX on 2025-12-16. The shares were previously bought for an average price of USD 7.2023. The Novavax Inc shares were sold for -9.2% lower than average price of previous purchases. This resulted in an overall loss of USD 180 The average price that the ETF previously sold NVAX share for is USD 7.63691 which is higher than the selling price of USD 6.54 on 2025-12-16. |
| NVAX - Hana Microelectronics Public Company Limited | SELL | -272 @ USD 6.54 | USD -1,779 | The ETF sold 272 shares of NVAX on 2025-12-16. The shares were previously bought for an average price of USD 7.2023. The Hana Microelectronics Public Company Limited shares were sold for -9.2% lower than average price of previous purchases. This resulted in an overall loss of USD 180 The average price that the ETF previously sold NVAX share for is USD 7.63691 which is higher than the selling price of USD 6.54 on 2025-12-16. |
| ERAS - Erasca Inc | SELL | -510 @ USD 3.52 | USD -1,795 | The ETF sold 510 shares of ERAS on 2025-12-16. The shares were previously bought for an average price of USD 2.02691. The Erasca Inc shares were sold for 73.7% higher than average price of previous purchases. This sale made a profit of USD 761 The average price that the ETF previously sold ERAS share for is USD 1.99815 so the ETF has sold 510 shares on 2025-12-16 at a higher price than the previous selling average. |
| GRFS - Grifols SA ADR | SELL | -204 @ USD 8.96 | USD -1,828 | The ETF sold 204 shares of GRFS on 2025-12-16. The shares were previously bought for an average price of USD 9.21387. The Grifols SA ADR shares were sold for -2.8% lower than average price of previous purchases. This resulted in an overall loss of USD 52 The average price that the ETF previously sold GRFS share for is USD 8.45547 so the ETF has sold 204 shares on 2025-12-16 at a higher price than the previous selling average. |
| AMLX - Amylyx Pharmaceuticals Inc | SELL | -149 @ USD 12.31 | USD -1,834 | The ETF sold 149 shares of AMLX on 2025-12-16. The shares were previously bought for an average price of USD 8.41455. The Amylyx Pharmaceuticals Inc shares were sold for 46.3% higher than average price of previous purchases. This sale made a profit of USD 580 The average price that the ETF previously sold AMLX share for is USD 7.89513 so the ETF has sold 149 shares on 2025-12-16 at a higher price than the previous selling average. |
| PHAT - Phathom Pharmaceuticals Inc | SELL | -121 @ USD 15.24 | USD -1,844 | The ETF sold 121 shares of PHAT on 2025-12-16. The shares were previously bought for an average price of USD 10.5456. The Phathom Pharmaceuticals Inc shares were sold for 44.5% higher than average price of previous purchases. This sale made a profit of USD 568 The average price that the ETF previously sold PHAT share for is USD 7.72727 so the ETF has sold 121 shares on 2025-12-16 at a higher price than the previous selling average. |
| SPRY - Silverback Therapeutics Inc | SELL | -174 @ USD 10.66 | USD -1,855 | The ETF sold 174 shares of SPRY on 2025-12-16. The shares were previously bought for an average price of USD 12.4193. The Silverback Therapeutics Inc shares were sold for -14.2% lower than average price of previous purchases. This resulted in an overall loss of USD 306 The average price that the ETF previously sold SPRY share for is USD 12.0498 which is higher than the selling price of USD 10.66 on 2025-12-16. |
| SVRA - Savara Inc | SELL | -289 @ USD 6.43 | USD -1,858 | The ETF sold 289 shares of SVRA on 2025-12-16. The shares were previously bought for an average price of USD 3.7196. The Savara Inc shares were sold for 72.9% higher than average price of previous purchases. This sale made a profit of USD 783 The average price that the ETF previously sold SVRA share for is USD 2.91627 so the ETF has sold 289 shares on 2025-12-16 at a higher price than the previous selling average. |
| CSTL - Castle Biosciences Inc | SELL | -48 @ USD 39.05 | USD -1,874 | The ETF sold 48 shares of CSTL on 2025-12-16. The shares were previously bought for an average price of USD 26.271. The Castle Biosciences Inc shares were sold for 48.6% higher than average price of previous purchases. This sale made a profit of USD 613 The average price that the ETF previously sold CSTL share for is USD 23.7149 so the ETF has sold 48 shares on 2025-12-16 at a higher price than the previous selling average. |
| URGN - UroGen Pharma Ltd | SELL | -80 @ USD 23.47 | USD -1,878 | The ETF sold 80 shares of URGN on 2025-12-16. The shares were previously bought for an average price of USD 17.0229. The UroGen Pharma Ltd shares were sold for 37.9% higher than average price of previous purchases. This sale made a profit of USD 516 The average price that the ETF previously sold URGN share for is USD 13.0179 so the ETF has sold 80 shares on 2025-12-16 at a higher price than the previous selling average. |
| PCRX - Pacira BioSciences, Inc. | SELL | -75 @ USD 26.18 | USD -1,964 | The ETF sold 75 shares of PCRX on 2025-12-16. The shares were previously bought for an average price of USD 23.8626. The Pacira BioSciences, Inc. shares were sold for 9.7% higher than average price of previous purchases. This sale made a profit of USD 174 The average price that the ETF previously sold PCRX share for is USD 21.985 so the ETF has sold 75 shares on 2025-12-16 at a higher price than the previous selling average. |
| XNCR - Xencor Inc | SELL | -119 @ USD 16.55 | USD -1,969 | The ETF sold 119 shares of XNCR on 2025-12-16. The shares were previously bought for an average price of USD 12.5279. The Xencor Inc shares were sold for 32.1% higher than average price of previous purchases. This sale made a profit of USD 479 The average price that the ETF previously sold XNCR share for is USD 12.9189 so the ETF has sold 119 shares on 2025-12-16 at a higher price than the previous selling average. |
| AMPH - Amphastar P | SELL | -77 @ USD 25.61 | USD -1,972 | The ETF sold 77 shares of AMPH on 2025-12-16. The shares were previously bought for an average price of USD 25.8292. The Amphastar P shares were sold for -0.8% lower than average price of previous purchases. This resulted in an overall loss of USD 17 The average price that the ETF previously sold AMPH share for is USD 31.4223 which is higher than the selling price of USD 25.61 on 2025-12-16. |
| PGEN - Precigen Inc | SELL | -511 @ USD 3.87 | USD -1,978 | The ETF sold 511 shares of PGEN on 2025-12-16. The shares were previously bought for an average price of USD 2.70172. The Precigen Inc shares were sold for 43.2% higher than average price of previous purchases. This sale made a profit of USD 597 The average price that the ETF previously sold PGEN share for is USD 1.71902 so the ETF has sold 511 shares on 2025-12-16 at a higher price than the previous selling average. |
| XERS - Xeris Pharmaceuticals Inc | SELL | -279 @ USD 7.1 | USD -1,981 | The ETF sold 279 shares of XERS on 2025-12-16. The shares were previously bought for an average price of USD 6.22689. The Xeris Pharmaceuticals Inc shares were sold for 14.0% higher than average price of previous purchases. This sale made a profit of USD 244 The average price that the ETF previously sold XERS share for is USD 4.7992 so the ETF has sold 279 shares on 2025-12-16 at a higher price than the previous selling average. |
| QURE - Uniqure NV | SELL | -92 @ USD 21.89 | USD -2,014 | The ETF sold 92 shares of QURE on 2025-12-16. The shares were previously bought for an average price of USD 23.4439. The Uniqure NV shares were sold for -6.6% lower than average price of previous purchases. This resulted in an overall loss of USD 143 The average price that the ETF previously sold QURE share for is USD 22.2098 which is higher than the selling price of USD 21.89 on 2025-12-16. |
| ANAB - AnaptysBio Inc | SELL | -46 @ USD 45.03 | USD -2,071 | The ETF sold 46 shares of ANAB on 2025-12-16. The shares were previously bought for an average price of USD 28.5512. The AnaptysBio Inc shares were sold for 57.7% higher than average price of previous purchases. This sale made a profit of USD 758 The average price that the ETF previously sold ANAB share for is USD 19.3412 so the ETF has sold 46 shares on 2025-12-16 at a higher price than the previous selling average. |
| DVAX - Dynavax Technologies Corporation | SELL | -196 @ USD 10.78 | USD -2,113 | The ETF sold 196 shares of DVAX on 2025-12-16. The shares were previously bought for an average price of USD 10.6546. The Dynavax Technologies Corporation shares were sold for 1.2% higher than average price of previous purchases. This sale made a profit of USD 25 The average price that the ETF previously sold DVAX share for is USD 11.8921 which is higher than the selling price of USD 10.78 on 2025-12-16. |
| INVA - Innoviva Inc | SELL | -109 @ USD 19.92 | USD -2,171 | The ETF sold 109 shares of INVA on 2025-12-16. The shares were previously bought for an average price of USD 19.6062. The Innoviva Inc shares were sold for 1.6% higher than average price of previous purchases. This sale made a profit of USD 34 The average price that the ETF previously sold INVA share for is USD 18.1906 so the ETF has sold 109 shares on 2025-12-16 at a higher price than the previous selling average. |
| GMAB - Genmab AS | SELL | -70 @ USD 31.35 | USD -2,195 | The ETF sold 70 shares of GMAB on 2025-12-16. The shares were previously bought for an average price of USD 25.5228. The Genmab AS shares were sold for 22.8% higher than average price of previous purchases. This sale made a profit of USD 408 The average price that the ETF previously sold GMAB share for is USD 22.7487 so the ETF has sold 70 shares on 2025-12-16 at a higher price than the previous selling average. |
| SANA - Sana Biotechnology Inc | SELL | -439 @ USD 5 | USD -2,195 | The ETF sold 439 shares of SANA on 2025-12-16. The shares were previously bought for an average price of USD 3.49243. The Sana Biotechnology Inc shares were sold for 43.2% higher than average price of previous purchases. This sale made a profit of USD 662 The average price that the ETF previously sold SANA share for is USD 2.4215 so the ETF has sold 439 shares on 2025-12-16 at a higher price than the previous selling average. |
| NVCR - Novocure Ltd | SELL | -186 @ USD 12.93 | USD -2,405 | The ETF sold 186 shares of NVCR on 2025-12-16. The shares were previously bought for an average price of USD 15.3912. The Novocure Ltd shares were sold for -16.0% lower than average price of previous purchases. This resulted in an overall loss of USD 458 The average price that the ETF previously sold NVCR share for is USD 19.629 which is higher than the selling price of USD 12.93 on 2025-12-16. |
| ARDX - Ardelyx Inc | SELL | -402 @ USD 6 | USD -2,412 | The ETF sold 402 shares of ARDX on 2025-12-16. The shares were previously bought for an average price of USD 4.92786. The Ardelyx Inc shares were sold for 21.8% higher than average price of previous purchases. This sale made a profit of USD 431 The average price that the ETF previously sold ARDX share for is USD 5.2192 so the ETF has sold 402 shares on 2025-12-16 at a higher price than the previous selling average. |
| FTRE - Fortrea Holdings Inc. | SELL | -151 @ USD 15.99 | USD -2,414 | The ETF sold 151 shares of FTRE on 2025-12-16. The shares were previously bought for an average price of USD 8.4198. The Fortrea Holdings Inc. shares were sold for 89.9% higher than average price of previous purchases. This sale made a profit of USD 1,143 The average price that the ETF previously sold FTRE share for is USD 12.7232 so the ETF has sold 151 shares on 2025-12-16 at a higher price than the previous selling average. |
| RLAY - Relay Therapeutics Inc | SELL | -288 @ USD 8.48 | USD -2,442 | The ETF sold 288 shares of RLAY on 2025-12-16. The shares were previously bought for an average price of USD 4.90988. The Relay Therapeutics Inc shares were sold for 72.7% higher than average price of previous purchases. This sale made a profit of USD 1,028 The average price that the ETF previously sold RLAY share for is USD 4.00775 so the ETF has sold 288 shares on 2025-12-16 at a higher price than the previous selling average. |
| IMCR - Immunocore Holdings Ltd | SELL | -68 @ USD 36.21 | USD -2,462 | The ETF sold 68 shares of IMCR on 2025-12-16. The shares were previously bought for an average price of USD 34.3094. The Immunocore Holdings Ltd shares were sold for 5.5% higher than average price of previous purchases. This sale made a profit of USD 129 The average price that the ETF previously sold IMCR share for is USD 30.8291 so the ETF has sold 68 shares on 2025-12-16 at a higher price than the previous selling average. |
| NRIX - Nurix Therapeutics Inc | SELL | -134 @ USD 18.84 | USD -2,525 | The ETF sold 134 shares of NRIX on 2025-12-16. The shares were previously bought for an average price of USD 13.2326. The Nurix Therapeutics Inc shares were sold for 42.4% higher than average price of previous purchases. This sale made a profit of USD 751 The average price that the ETF previously sold NRIX share for is USD 14.2205 so the ETF has sold 134 shares on 2025-12-16 at a higher price than the previous selling average. |
| COLL - Collegium Pharmaceutical Inc | SELL | -52 @ USD 48.71 | USD -2,533 | The ETF sold 52 shares of COLL on 2025-12-16. The shares were previously bought for an average price of USD 35.6563. The Collegium Pharmaceutical Inc shares were sold for 36.6% higher than average price of previous purchases. This sale made a profit of USD 679 The average price that the ETF previously sold COLL share for is USD 31.0397 so the ETF has sold 52 shares on 2025-12-16 at a higher price than the previous selling average. |
| AGIO - Agios Pharm | SELL | -100 @ USD 26.09 | USD -2,609 | The ETF sold 100 shares of AGIO on 2025-12-16. The shares were previously bought for an average price of USD 33.9293. The Agios Pharm shares were sold for -23.1% lower than average price of previous purchases. This resulted in an overall loss of USD 784 The average price that the ETF previously sold AGIO share for is USD 35.8368 which is higher than the selling price of USD 26.09 on 2025-12-16. |
| TSHA - Taysha Gene Therapies Inc | SELL | -455 @ USD 5.82 | USD -2,648 | The ETF sold 455 shares of TSHA on 2025-12-16. The shares were previously bought for an average price of USD 3.26801. The Taysha Gene Therapies Inc shares were sold for 78.1% higher than average price of previous purchases. This sale made a profit of USD 1,161 The average price that the ETF previously sold TSHA share for is USD 2.09762 so the ETF has sold 455 shares on 2025-12-16 at a higher price than the previous selling average. |
| BCRX - BioCryst Pharmaceuticals Inc | SELL | -363 @ USD 7.47 | USD -2,712 | The ETF sold 363 shares of BCRX on 2025-12-16. The shares were previously bought for an average price of USD 8.03142. The BioCryst Pharmaceuticals Inc shares were sold for -7.0% lower than average price of previous purchases. This resulted in an overall loss of USD 204 The average price that the ETF previously sold BCRX share for is USD 7.55588 which is higher than the selling price of USD 7.47 on 2025-12-16. |
| HROW - Harrow Health Inc | SELL | -64 @ USD 44.77 | USD -2,865 | The ETF sold 64 shares of HROW on 2025-12-16. The shares were previously bought for an average price of USD 37.118. The Harrow Health Inc shares were sold for 20.6% higher than average price of previous purchases. This sale made a profit of USD 490 The average price that the ETF previously sold HROW share for is USD 33.3704 so the ETF has sold 64 shares on 2025-12-16 at a higher price than the previous selling average. |
| ANIP - ANI Pharmaceuticals Inc | SELL | -37 @ USD 81.1 | USD -3,001 | The ETF sold 37 shares of ANIP on 2025-12-16. The shares were previously bought for an average price of USD 74.884. The ANI Pharmaceuticals Inc shares were sold for 8.3% higher than average price of previous purchases. This sale made a profit of USD 230 The average price that the ETF previously sold ANIP share for is USD 68.3195 so the ETF has sold 37 shares on 2025-12-16 at a higher price than the previous selling average. |
| TXG - 10X Genomics Inc | SELL | -192 @ USD 15.71 | USD -3,016 | The ETF sold 192 shares of TXG on 2025-12-16. The shares were previously bought for an average price of USD 13.611. The 10X Genomics Inc shares were sold for 15.4% higher than average price of previous purchases. This sale made a profit of USD 403 The average price that the ETF previously sold TXG share for is USD 10.823 so the ETF has sold 192 shares on 2025-12-16 at a higher price than the previous selling average. |
| TXG - Terex Corporation | SELL | -192 @ USD 15.71 | USD -3,016 | The ETF sold 192 shares of TXG on 2025-12-16. The shares were previously bought for an average price of USD 13.611. The Terex Corporation shares were sold for 15.4% higher than average price of previous purchases. This sale made a profit of USD 403 The average price that the ETF previously sold TXG share for is USD 10.823 so the ETF has sold 192 shares on 2025-12-16 at a higher price than the previous selling average. |
| KNSA - Kiniksa Pharmaceuticals Ltd | SELL | -73 @ USD 41.37 | USD -3,020 | The ETF sold 73 shares of KNSA on 2025-12-16. The shares were previously bought for an average price of USD 32.8049. The Kiniksa Pharmaceuticals Ltd shares were sold for 26.1% higher than average price of previous purchases. This sale made a profit of USD 625 The average price that the ETF previously sold KNSA share for is USD 23.6987 so the ETF has sold 73 shares on 2025-12-16 at a higher price than the previous selling average. |
| RXRX - Recursion Pharmaceuticals Inc | SELL | -724 @ USD 4.2 | USD -3,041 | The ETF sold 724 shares of RXRX on 2025-12-16. The shares were previously bought for an average price of USD 5.51461. The Recursion Pharmaceuticals Inc shares were sold for -23.8% lower than average price of previous purchases. This resulted in an overall loss of USD 952 The average price that the ETF previously sold RXRX share for is USD 5.49057 which is higher than the selling price of USD 4.2 on 2025-12-16. |
| LEGN - Legend Biotech Corp | SELL | -141 @ USD 21.65 | USD -3,053 | The ETF sold 141 shares of LEGN on 2025-12-16. The shares were previously bought for an average price of USD 32.7402. The Legend Biotech Corp shares were sold for -33.9% lower than average price of previous purchases. This resulted in an overall loss of USD 1,564 The average price that the ETF previously sold LEGN share for is USD 34.63 which is higher than the selling price of USD 21.65 on 2025-12-16. |
| SNDX - Syndax Pharmaceuticals Inc | SELL | -148 @ USD 20.72 | USD -3,067 | The ETF sold 148 shares of SNDX on 2025-12-16. The shares were previously bought for an average price of USD 14.0596. The Syndax Pharmaceuticals Inc shares were sold for 47.4% higher than average price of previous purchases. This sale made a profit of USD 986 The average price that the ETF previously sold SNDX share for is USD 13.4039 so the ETF has sold 148 shares on 2025-12-16 at a higher price than the previous selling average. |
| VCEL - Vericel Corp Ord | SELL | -87 @ USD 35.5 | USD -3,089 | The ETF sold 87 shares of VCEL on 2025-12-16. The shares were previously bought for an average price of USD 39.9007. The Vericel Corp Ord shares were sold for -11.0% lower than average price of previous purchases. This resulted in an overall loss of USD 383 The average price that the ETF previously sold VCEL share for is USD 44.8041 which is higher than the selling price of USD 35.5 on 2025-12-16. |
| STOK - Stoke Therapeutics Inc | SELL | -93 @ USD 33.61 | USD -3,126 | The ETF sold 93 shares of STOK on 2025-12-16. The shares were previously bought for an average price of USD 19.6492. The Stoke Therapeutics Inc shares were sold for 71.1% higher than average price of previous purchases. This sale made a profit of USD 1,298 The average price that the ETF previously sold STOK share for is USD 12.0342 so the ETF has sold 93 shares on 2025-12-16 at a higher price than the previous selling average. |
| MNKD - MannKind Corp | SELL | -529 @ USD 5.91 | USD -3,126 | The ETF sold 529 shares of MNKD on 2025-12-16. The shares were previously bought for an average price of USD 4.95458. The MannKind Corp shares were sold for 19.3% higher than average price of previous purchases. This sale made a profit of USD 505 The average price that the ETF previously sold MNKD share for is USD 5.54147 so the ETF has sold 529 shares on 2025-12-16 at a higher price than the previous selling average. |
| TWST - Twist Bioscience Corp | SELL | -104 @ USD 31.13 | USD -3,238 | The ETF sold 104 shares of TWST on 2025-12-16. The shares were previously bought for an average price of USD 34.6802. The Twist Bioscience Corp shares were sold for -10.2% lower than average price of previous purchases. This resulted in an overall loss of USD 369 The average price that the ETF previously sold TWST share for is USD 38.2852 which is higher than the selling price of USD 31.13 on 2025-12-16. |
| ZYME - Zymeworks Inc. Common Stock | SELL | -128 @ USD 25.85 | USD -3,309 | The ETF sold 128 shares of ZYME on 2025-12-16. The shares were previously bought for an average price of USD 17.3812. The Zymeworks Inc. Common Stock shares were sold for 48.7% higher than average price of previous purchases. This sale made a profit of USD 1,084 The average price that the ETF previously sold ZYME share for is USD 13.9875 so the ETF has sold 128 shares on 2025-12-16 at a higher price than the previous selling average. |
| SYRE - Spyre Therapeutics Inc. | SELL | -103 @ USD 32.97 | USD -3,396 | The ETF sold 103 shares of SYRE on 2025-12-16. The shares were previously bought for an average price of USD 21.6111. The Spyre Therapeutics Inc. shares were sold for 52.6% higher than average price of previous purchases. This sale made a profit of USD 1,170 The average price that the ETF previously sold SYRE share for is USD 16.8021 so the ETF has sold 103 shares on 2025-12-16 at a higher price than the previous selling average. |
| AVDL - Avadel Pharmaceuticals PLC | SELL | -161 @ USD 21.37 | USD -3,441 | The ETF sold 161 shares of AVDL on 2025-12-16. The shares were previously bought for an average price of USD 13.7243. The Avadel Pharmaceuticals PLC shares were sold for 55.7% higher than average price of previous purchases. This sale made a profit of USD 1,231 The average price that the ETF previously sold AVDL share for is USD 11.3057 so the ETF has sold 161 shares on 2025-12-16 at a higher price than the previous selling average. |
| IBRX - Immunitybio Inc | SELL | -1,594 @ USD 2.16 | USD -3,443 | The ETF sold 1594 shares of IBRX on 2025-12-16. The shares were previously bought for an average price of USD 2.6304. The Immunitybio Inc shares were sold for -17.9% lower than average price of previous purchases. This resulted in an overall loss of USD 750 The average price that the ETF previously sold IBRX share for is USD 3.00506 which is higher than the selling price of USD 2.16 on 2025-12-16. |
| AUPH - Aurinia Pharmaceuticals Inc | SELL | -226 @ USD 15.85 | USD -3,582 | The ETF sold 226 shares of AUPH on 2025-12-16. The shares were previously bought for an average price of USD 11.3392. The Aurinia Pharmaceuticals Inc shares were sold for 39.8% higher than average price of previous purchases. This sale made a profit of USD 1,019 The average price that the ETF previously sold AUPH share for is USD 9.59974 so the ETF has sold 226 shares on 2025-12-16 at a higher price than the previous selling average. |
| SRPT - Sarepta Therapeutics Inc | SELL | -167 @ USD 22.31 | USD -3,726 | The ETF sold 167 shares of SRPT on 2025-12-16. The shares were previously bought for an average price of USD 30.0903. The Sarepta Therapeutics Inc shares were sold for -25.9% lower than average price of previous purchases. This resulted in an overall loss of USD 1,299 The average price that the ETF previously sold SRPT share for is USD 74.2495 which is higher than the selling price of USD 22.31 on 2025-12-16. |
| HRMY - Harmony Biosciences Holdings | SELL | -98 @ USD 38.83 | USD -3,805 | The ETF sold 98 shares of HRMY on 2025-12-16. The shares were previously bought for an average price of USD 33.4492. The Harmony Biosciences Holdings shares were sold for 16.1% higher than average price of previous purchases. This sale made a profit of USD 527 The average price that the ETF previously sold HRMY share for is USD 32.0582 so the ETF has sold 98 shares on 2025-12-16 at a higher price than the previous selling average. |
| OLMA - Olema Pharmaceuticals Inc | SELL | -116 @ USD 34.28 | USD -3,976 | The ETF sold 116 shares of OLMA on 2025-12-16. The shares were previously bought for an average price of USD 11.1658. The Olema Pharmaceuticals Inc shares were sold for 207.0% higher than average price of previous purchases. This sale made a profit of USD 2,681 The average price that the ETF previously sold OLMA share for is USD 6.81641 so the ETF has sold 116 shares on 2025-12-16 at a higher price than the previous selling average. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | SELL | -113 @ USD 36.04 | USD -4,073 | The ETF sold 113 shares of MLYS on 2025-12-16. The shares were previously bought for an average price of USD 24.5678. The Mineralys Therapeutics, Inc. Common Stock shares were sold for 46.7% higher than average price of previous purchases. This sale made a profit of USD 1,296 The average price that the ETF previously sold MLYS share for is USD 17.5548 so the ETF has sold 113 shares on 2025-12-16 at a higher price than the previous selling average. |
| EWTX - Edgewise Therapeutics Inc | SELL | -179 @ USD 22.77 | USD -4,076 | The ETF sold 179 shares of EWTX on 2025-12-16. The shares were previously bought for an average price of USD 17.9438. The Edgewise Therapeutics Inc shares were sold for 26.9% higher than average price of previous purchases. This sale made a profit of USD 864 The average price that the ETF previously sold EWTX share for is USD 21.888 so the ETF has sold 179 shares on 2025-12-16 at a higher price than the previous selling average. |
| ADPT - Adaptive Biotechnologies Corp | SELL | -259 @ USD 15.93 | USD -4,126 | The ETF sold 259 shares of ADPT on 2025-12-16. The shares were previously bought for an average price of USD 13.4506. The Adaptive Biotechnologies Corp shares were sold for 18.4% higher than average price of previous purchases. This sale made a profit of USD 642 The average price that the ETF previously sold ADPT share for is USD 8.15229 so the ETF has sold 259 shares on 2025-12-16 at a higher price than the previous selling average. |
| CNTA - Centessa Pharmaceuticals PLC ADR | SELL | -163 @ USD 25.72 | USD -4,192 | The ETF sold 163 shares of CNTA on 2025-12-16. The shares were previously bought for an average price of USD 19.5396. The Centessa Pharmaceuticals PLC ADR shares were sold for 31.6% higher than average price of previous purchases. This sale made a profit of USD 1,007 The average price that the ETF previously sold CNTA share for is USD 17.2894 so the ETF has sold 163 shares on 2025-12-16 at a higher price than the previous selling average. |
| DNLI - Denali Therapeutics Inc | SELL | -249 @ USD 17.02 | USD -4,238 | The ETF sold 249 shares of DNLI on 2025-12-16. The shares were previously bought for an average price of USD 16.1568. The Denali Therapeutics Inc shares were sold for 5.3% higher than average price of previous purchases. This sale made a profit of USD 215 The average price that the ETF previously sold DNLI share for is USD 17.2835 which is higher than the selling price of USD 17.02 on 2025-12-16. |
| OCUL - Ocular Therapeutix Inc | SELL | -296 @ USD 14.39 | USD -4,259 | The ETF sold 296 shares of OCUL on 2025-12-16. The shares were previously bought for an average price of USD 10.7426. The Ocular Therapeutix Inc shares were sold for 34.0% higher than average price of previous purchases. This sale made a profit of USD 1,080 The average price that the ETF previously sold OCUL share for is USD 8.68815 so the ETF has sold 296 shares on 2025-12-16 at a higher price than the previous selling average. |
| WVE - Wave Life Sciences Ltd | SELL | -271 @ USD 16.41 | USD -4,447 | The ETF sold 271 shares of WVE on 2025-12-16. The shares were previously bought for an average price of USD 8.32371. The Wave Life Sciences Ltd shares were sold for 97.1% higher than average price of previous purchases. This sale made a profit of USD 2,191 The average price that the ETF previously sold WVE share for is USD 8.58431 so the ETF has sold 271 shares on 2025-12-16 at a higher price than the previous selling average. |
| SUPN - Supernus Pharmaceuticals Inc | SELL | -94 @ USD 48.32 | USD -4,542 | The ETF sold 94 shares of SUPN on 2025-12-16. The shares were previously bought for an average price of USD 39.4199. The Supernus Pharmaceuticals Inc shares were sold for 22.6% higher than average price of previous purchases. This sale made a profit of USD 837 The average price that the ETF previously sold SUPN share for is USD 37.1014 so the ETF has sold 94 shares on 2025-12-16 at a higher price than the previous selling average. |
| BEAM - Beam Therapeutics Inc | SELL | -172 @ USD 26.76 | USD -4,603 | The ETF sold 172 shares of BEAM on 2025-12-16. The shares were previously bought for an average price of USD 21.9707. The Beam Therapeutics Inc shares were sold for 21.8% higher than average price of previous purchases. This sale made a profit of USD 824 The average price that the ETF previously sold BEAM share for is USD 22.6368 so the ETF has sold 172 shares on 2025-12-16 at a higher price than the previous selling average. |
| DYN - Dyne Therapeutics Inc | SELL | -239 @ USD 19.55 | USD -4,672 | The ETF sold 239 shares of DYN on 2025-12-16. The shares were previously bought for an average price of USD 14.4536. The Dyne Therapeutics Inc shares were sold for 35.3% higher than average price of previous purchases. This sale made a profit of USD 1,218 The average price that the ETF previously sold DYN share for is USD 17.2505 so the ETF has sold 239 shares on 2025-12-16 at a higher price than the previous selling average. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | SELL | -239 @ USD 19.55 | USD -4,672 | The ETF sold 239 shares of DYN on 2025-12-16. The shares were previously bought for an average price of USD 14.4536. The DYNAGREEN EN.PR.GR.H YC 1 shares were sold for 35.3% higher than average price of previous purchases. This sale made a profit of USD 1,218 The average price that the ETF previously sold DYN share for is USD 17.2505 so the ETF has sold 239 shares on 2025-12-16 at a higher price than the previous selling average. |
| CGON - CG Oncology, Inc. Common stock | SELL | -128 @ USD 37.85 | USD -4,845 | The ETF sold 128 shares of CGON on 2025-12-16. The shares were previously bought for an average price of USD 33.0567. The CG Oncology, Inc. Common stock shares were sold for 14.5% higher than average price of previous purchases. This sale made a profit of USD 614 The average price that the ETF previously sold CGON share for is USD 28.5025 so the ETF has sold 128 shares on 2025-12-16 at a higher price than the previous selling average. |
| IDYA - Ideaya Biosciences Inc | SELL | -148 @ USD 33.81 | USD -5,004 | The ETF sold 148 shares of IDYA on 2025-12-16. The shares were previously bought for an average price of USD 26.2583. The Ideaya Biosciences Inc shares were sold for 28.8% higher than average price of previous purchases. This sale made a profit of USD 1,118 The average price that the ETF previously sold IDYA share for is USD 22.9977 so the ETF has sold 148 shares on 2025-12-16 at a higher price than the previous selling average. |
| VERA - Vera Therapeutics Inc | SELL | -108 @ USD 48.3 | USD -5,216 | The ETF sold 108 shares of VERA on 2025-12-16. The shares were previously bought for an average price of USD 30.2541. The Vera Therapeutics Inc shares were sold for 59.6% higher than average price of previous purchases. This sale made a profit of USD 1,949 The average price that the ETF previously sold VERA share for is USD 28.536 so the ETF has sold 108 shares on 2025-12-16 at a higher price than the previous selling average. |
| GRAL - GRAIL, LLC | SELL | -60 @ USD 87.02 | USD -5,221 | The ETF sold 60 shares of GRAL on 2025-12-16. The shares were previously bought for an average price of USD 63.9902. The GRAIL, LLC shares were sold for 36.0% higher than average price of previous purchases. This sale made a profit of USD 1,382 The average price that the ETF previously sold GRAL share for is USD 34.1048 so the ETF has sold 60 shares on 2025-12-16 at a higher price than the previous selling average. |
| IRON - Ironveld Plc | SELL | -58 @ USD 91.47 | USD -5,305 | The ETF sold 58 shares of IRON on 2025-12-16. The shares were previously bought for an average price of USD 66.217. The Ironveld Plc shares were sold for 38.1% higher than average price of previous purchases. This sale made a profit of USD 1,465 The average price that the ETF previously sold IRON share for is USD 57.6299 so the ETF has sold 58 shares on 2025-12-16 at a higher price than the previous selling average. |
| APLS - Apellis Pharmaceuticals Inc | SELL | -212 @ USD 25.31 | USD -5,366 | The ETF sold 212 shares of APLS on 2025-12-16. The shares were previously bought for an average price of USD 21.1068. The Apellis Pharmaceuticals Inc shares were sold for 19.9% higher than average price of previous purchases. This sale made a profit of USD 891 The average price that the ETF previously sold APLS share for is USD 24.9471 so the ETF has sold 212 shares on 2025-12-16 at a higher price than the previous selling average. |
| TVTX - Travere Therapeutics Inc | SELL | -151 @ USD 35.85 | USD -5,413 | The ETF sold 151 shares of TVTX on 2025-12-16. The shares were previously bought for an average price of USD 24.1834. The Travere Therapeutics Inc shares were sold for 48.2% higher than average price of previous purchases. This sale made a profit of USD 1,762 The average price that the ETF previously sold TVTX share for is USD 19.6508 so the ETF has sold 151 shares on 2025-12-16 at a higher price than the previous selling average. |
| XENE - Xenon Pharmaceuticals Inc | SELL | -129 @ USD 43 | USD -5,547 | The ETF sold 129 shares of XENE on 2025-12-16. The shares were previously bought for an average price of USD 37.5806. The Xenon Pharmaceuticals Inc shares were sold for 14.4% higher than average price of previous purchases. This sale made a profit of USD 699 The average price that the ETF previously sold XENE share for is USD 36.3383 so the ETF has sold 129 shares on 2025-12-16 at a higher price than the previous selling average. |
| TARS - Tarsus Pharmaceuticals Inc | SELL | -71 @ USD 78.28 | USD -5,558 | The ETF sold 71 shares of TARS on 2025-12-16. The shares were previously bought for an average price of USD 56.6878. The Tarsus Pharmaceuticals Inc shares were sold for 38.1% higher than average price of previous purchases. This sale made a profit of USD 1,533 The average price that the ETF previously sold TARS share for is USD 50.8716 so the ETF has sold 71 shares on 2025-12-16 at a higher price than the previous selling average. |
| RARE - Ultragenyx | SELL | -162 @ USD 34.34 | USD -5,563 | The ETF sold 162 shares of RARE on 2025-12-16. The shares were previously bought for an average price of USD 35.8581. The Ultragenyx shares were sold for -4.2% lower than average price of previous purchases. This resulted in an overall loss of USD 246 The average price that the ETF previously sold RARE share for is USD 37.187 which is higher than the selling price of USD 34.34 on 2025-12-16. |
| RARE - WISETFWTMRARETFP | SELL | -162 @ USD 34.34 | USD -5,563 | The ETF sold 162 shares of RARE on 2025-12-16. The shares were previously bought for an average price of USD 35.8581. The WISETFWTMRARETFP shares were sold for -4.2% lower than average price of previous purchases. This resulted in an overall loss of USD 246 The average price that the ETF previously sold RARE share for is USD 37.187 which is higher than the selling price of USD 34.34 on 2025-12-16. |
| MIRM - Mirum Pharmaceuticals Inc | SELL | -84 @ USD 67.05 | USD -5,632 | The ETF sold 84 shares of MIRM on 2025-12-16. The shares were previously bought for an average price of USD 59.3746. The Mirum Pharmaceuticals Inc shares were sold for 12.9% higher than average price of previous purchases. This sale made a profit of USD 645 The average price that the ETF previously sold MIRM share for is USD 49.6453 so the ETF has sold 84 shares on 2025-12-16 at a higher price than the previous selling average. |
| FOLD - Amicus Therapeutics Inc | SELL | -523 @ USD 10.89 | USD -5,695 | The ETF sold 523 shares of FOLD on 2025-12-16. The shares were previously bought for an average price of USD 8.09081. The Amicus Therapeutics Inc shares were sold for 34.6% higher than average price of previous purchases. This sale made a profit of USD 1,464 The average price that the ETF previously sold FOLD share for is USD 8.52901 so the ETF has sold 523 shares on 2025-12-16 at a higher price than the previous selling average. |
| VCYT - Veracyte Inc | SELL | -132 @ USD 43.22 | USD -5,705 | The ETF sold 132 shares of VCYT on 2025-12-16. The shares were previously bought for an average price of USD 34.9468. The Veracyte Inc shares were sold for 23.7% higher than average price of previous purchases. This sale made a profit of USD 1,092 The average price that the ETF previously sold VCYT share for is USD 34.1367 so the ETF has sold 132 shares on 2025-12-16 at a higher price than the previous selling average. |
| ARQT - Arcutis Biotherapeutics Inc | SELL | -202 @ USD 28.53 | USD -5,763 | The ETF sold 202 shares of ARQT on 2025-12-16. The shares were previously bought for an average price of USD 20.1616. The Arcutis Biotherapeutics Inc shares were sold for 41.5% higher than average price of previous purchases. This sale made a profit of USD 1,690 The average price that the ETF previously sold ARQT share for is USD 14.693 so the ETF has sold 202 shares on 2025-12-16 at a higher price than the previous selling average. |
| APGE - Apogee Therapeutics, Inc. Common Stock | SELL | -78 @ USD 74.78 | USD -5,833 | The ETF sold 78 shares of APGE on 2025-12-16. The shares were previously bought for an average price of USD 52.0132. The Apogee Therapeutics, Inc. Common Stock shares were sold for 43.8% higher than average price of previous purchases. This sale made a profit of USD 1,776 The average price that the ETF previously sold APGE share for is USD 41.5168 so the ETF has sold 78 shares on 2025-12-16 at a higher price than the previous selling average. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | SELL | -100 @ USD 61.71 | USD -6,171 | The ETF sold 100 shares of GPCR on 2025-12-16. The shares were previously bought for an average price of USD 27.9063. The Structure Therapeutics Inc. American Depositary Shares shares were sold for 121.1% higher than average price of previous purchases. This sale made a profit of USD 3,380 The average price that the ETF previously sold GPCR share for is USD 24.2569 so the ETF has sold 100 shares on 2025-12-16 at a higher price than the previous selling average. |
| ACLX - Arcellx Inc | SELL | -94 @ USD 66.33 | USD -6,235 | The ETF sold 94 shares of ACLX on 2025-12-16. The shares were previously bought for an average price of USD 72.202. The Arcellx Inc shares were sold for -8.1% lower than average price of previous purchases. This resulted in an overall loss of USD 552 The average price that the ETF previously sold ACLX share for is USD 75.4152 which is higher than the selling price of USD 66.33 on 2025-12-16. |
| TERN - Tern Plc | SELL | -148 @ USD 42.92 | USD -6,352 | The ETF sold 148 shares of TERN on 2025-12-16. The shares were previously bought for an average price of USD 11.663. The Tern Plc shares were sold for 268.0% higher than average price of previous purchases. This sale made a profit of USD 4,626 The average price that the ETF previously sold TERN share for is USD 6.17524 so the ETF has sold 148 shares on 2025-12-16 at a higher price than the previous selling average. |
| LGND - Ligand Pharmaceuticals Incorporated | SELL | -33 @ USD 192.63 | USD -6,357 | The ETF sold 33 shares of LGND on 2025-12-16. The shares were previously bought for an average price of USD 149.15. The Ligand Pharmaceuticals Incorporated shares were sold for 29.2% higher than average price of previous purchases. This sale made a profit of USD 1,435 The average price that the ETF previously sold LGND share for is USD 123.986 so the ETF has sold 33 shares on 2025-12-16 at a higher price than the previous selling average. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | SELL | -528 @ USD 12.17 | USD -6,426 | The ETF sold 528 shares of AMRX on 2025-12-16. The shares were previously bought for an average price of USD 9.64518. The Amneal Pharmaceuticals, Inc. Class A Common Stock shares were sold for 26.2% higher than average price of previous purchases. This sale made a profit of USD 1,333 The average price that the ETF previously sold AMRX share for is USD 8.84209 so the ETF has sold 528 shares on 2025-12-16 at a higher price than the previous selling average. |
| SRRK - Scholar Rock Holding Corp | SELL | -161 @ USD 44.32 | USD -7,136 | The ETF sold 161 shares of SRRK on 2025-12-16. The shares were previously bought for an average price of USD 36.9163. The Scholar Rock Holding Corp shares were sold for 20.1% higher than average price of previous purchases. This sale made a profit of USD 1,192 The average price that the ETF previously sold SRRK share for is USD 32.0667 so the ETF has sold 161 shares on 2025-12-16 at a higher price than the previous selling average. |
| ACAD - ACADIA Pharmaceuticals Inc | SELL | -283 @ USD 26.8 | USD -7,584 | The ETF sold 283 shares of ACAD on 2025-12-16. The shares were previously bought for an average price of USD 22.0973. The ACADIA Pharmaceuticals Inc shares were sold for 21.3% higher than average price of previous purchases. This sale made a profit of USD 1,331 The average price that the ETF previously sold ACAD share for is USD 18.2391 so the ETF has sold 283 shares on 2025-12-16 at a higher price than the previous selling average. |
| ADMA - ADMA Biologics Inc | SELL | -400 @ USD 19.17 | USD -7,668 | The ETF sold 400 shares of ADMA on 2025-12-16. The shares were previously bought for an average price of USD 17.8309. The ADMA Biologics Inc shares were sold for 7.5% higher than average price of previous purchases. This sale made a profit of USD 536 The average price that the ETF previously sold ADMA share for is USD 17.7365 so the ETF has sold 400 shares on 2025-12-16 at a higher price than the previous selling average. |
| CRNX - Crinetics Pharmaceuticals Inc | SELL | -159 @ USD 48.61 | USD -7,729 | The ETF sold 159 shares of CRNX on 2025-12-16. The shares were previously bought for an average price of USD 37.9409. The Crinetics Pharmaceuticals Inc shares were sold for 28.1% higher than average price of previous purchases. This sale made a profit of USD 1,696 The average price that the ETF previously sold CRNX share for is USD 36.6088 so the ETF has sold 159 shares on 2025-12-16 at a higher price than the previous selling average. |
| IMVT - Immunovant Inc | SELL | -293 @ USD 26.61 | USD -7,797 | The ETF sold 293 shares of IMVT on 2025-12-16. The shares were previously bought for an average price of USD 19.1832. The Immunovant Inc shares were sold for 38.7% higher than average price of previous purchases. This sale made a profit of USD 2,176 The average price that the ETF previously sold IMVT share for is USD 20.0604 so the ETF has sold 293 shares on 2025-12-16 at a higher price than the previous selling average. |
| ALKS - Alkermes Plc | SELL | -279 @ USD 28.06 | USD -7,829 | The ETF sold 279 shares of ALKS on 2025-12-16. The shares were previously bought for an average price of USD 30.05. The Alkermes Plc shares were sold for -6.6% lower than average price of previous purchases. This resulted in an overall loss of USD 555 The average price that the ETF previously sold ALKS share for is USD 29.4611 which is higher than the selling price of USD 28.06 on 2025-12-16. |
| CRSP - Crispr Therapeutics AG | SELL | -153 @ USD 55.97 | USD -8,563 | The ETF sold 153 shares of CRSP on 2025-12-16. The shares were previously bought for an average price of USD 53.3058. The Crispr Therapeutics AG shares were sold for 5.0% higher than average price of previous purchases. This sale made a profit of USD 408 The average price that the ETF previously sold CRSP share for is USD 43.5302 so the ETF has sold 153 shares on 2025-12-16 at a higher price than the previous selling average. |
| COGT - Cogent Biosciences Inc | SELL | -236 @ USD 39.99 | USD -9,438 | The ETF sold 236 shares of COGT on 2025-12-16. The shares were previously bought for an average price of USD 18.29. The Cogent Biosciences Inc shares were sold for 118.6% higher than average price of previous purchases. This sale made a profit of USD 5,121 The average price that the ETF previously sold COGT share for is USD 9.34159 so the ETF has sold 236 shares on 2025-12-16 at a higher price than the previous selling average. |
| PCVX - Vaxcyte Inc | SELL | -219 @ USD 43.67 | USD -9,564 | The ETF sold 219 shares of PCVX on 2025-12-16. The shares were previously bought for an average price of USD 45.0066. The Vaxcyte Inc shares were sold for -3.0% lower than average price of previous purchases. This resulted in an overall loss of USD 293 The average price that the ETF previously sold PCVX share for is USD 52.4178 which is higher than the selling price of USD 43.67 on 2025-12-16. |
| PRAX - Praxis Precision Medicines Inc | SELL | -35 @ USD 274.51 | USD -9,608 | The ETF sold 35 shares of PRAX on 2025-12-16. The shares were previously bought for an average price of USD 98.2598. The Praxis Precision Medicines Inc shares were sold for 179.4% higher than average price of previous purchases. This sale made a profit of USD 6,169 The average price that the ETF previously sold PRAX share for is USD 58.7419 so the ETF has sold 35 shares on 2025-12-16 at a higher price than the previous selling average. |
| PTGX - Protagonist Therapeutics Inc | SELL | -105 @ USD 91.54 | USD -9,612 | The ETF sold 105 shares of PTGX on 2025-12-16. The shares were previously bought for an average price of USD 64.886. The Protagonist Therapeutics Inc shares were sold for 41.1% higher than average price of previous purchases. This sale made a profit of USD 2,799 The average price that the ETF previously sold PTGX share for is USD 50.1589 so the ETF has sold 105 shares on 2025-12-16 at a higher price than the previous selling average. |
| KYMR - Kymera Therapeutics Inc | SELL | -120 @ USD 84.19 | USD -10,103 | The ETF sold 120 shares of KYMR on 2025-12-16. The shares were previously bought for an average price of USD 52.5563. The Kymera Therapeutics Inc shares were sold for 60.2% higher than average price of previous purchases. This sale made a profit of USD 3,796 The average price that the ETF previously sold KYMR share for is USD 38.7214 so the ETF has sold 120 shares on 2025-12-16 at a higher price than the previous selling average. |
| PTCT - PTC Therapeutics Inc | SELL | -134 @ USD 75.42 | USD -10,106 | The ETF sold 134 shares of PTCT on 2025-12-16. The shares were previously bought for an average price of USD 61.273. The PTC Therapeutics Inc shares were sold for 23.1% higher than average price of previous purchases. This sale made a profit of USD 1,896 The average price that the ETF previously sold PTCT share for is USD 49.6368 so the ETF has sold 134 shares on 2025-12-16 at a higher price than the previous selling average. |
| NUVL - Nuvalent Inc | SELL | -112 @ USD 102.63 | USD -11,495 | The ETF sold 112 shares of NUVL on 2025-12-16. The shares were previously bought for an average price of USD 88.7259. The Nuvalent Inc shares were sold for 15.7% higher than average price of previous purchases. This sale made a profit of USD 1,557 The average price that the ETF previously sold NUVL share for is USD 79.1834 so the ETF has sold 112 shares on 2025-12-16 at a higher price than the previous selling average. |
| KRYS - Krystal Biotech Inc | SELL | -49 @ USD 238.55 | USD -11,689 | The ETF sold 49 shares of KRYS on 2025-12-16. The shares were previously bought for an average price of USD 177.51. The Krystal Biotech Inc shares were sold for 34.4% higher than average price of previous purchases. This sale made a profit of USD 2,991 The average price that the ETF previously sold KRYS share for is USD 166.939 so the ETF has sold 49 shares on 2025-12-16 at a higher price than the previous selling average. |
| AXSM - Axsome Therapeutics Inc | SELL | -84 @ USD 146.87 | USD -12,337 | The ETF sold 84 shares of AXSM on 2025-12-16. The shares were previously bought for an average price of USD 123.568. The Axsome Therapeutics Inc shares were sold for 18.9% higher than average price of previous purchases. This sale made a profit of USD 1,957 The average price that the ETF previously sold AXSM share for is USD 104.466 so the ETF has sold 84 shares on 2025-12-16 at a higher price than the previous selling average. |
| CYTK - Cytokinetics Inc | SELL | -200 @ USD 62.02 | USD -12,404 | The ETF sold 200 shares of CYTK on 2025-12-16. The shares were previously bought for an average price of USD 48.9512. The Cytokinetics Inc shares were sold for 26.7% higher than average price of previous purchases. This sale made a profit of USD 2,614 The average price that the ETF previously sold CYTK share for is USD 45.7985 so the ETF has sold 200 shares on 2025-12-16 at a higher price than the previous selling average. |
| RYTM - Rhythm Pharmaceuticals Inc | SELL | -112 @ USD 112.45 | USD -12,594 | The ETF sold 112 shares of RYTM on 2025-12-16. The shares were previously bought for an average price of USD 83.781. The Rhythm Pharmaceuticals Inc shares were sold for 34.2% higher than average price of previous purchases. This sale made a profit of USD 3,211 The average price that the ETF previously sold RYTM share for is USD 64.0007 so the ETF has sold 112 shares on 2025-12-16 at a higher price than the previous selling average. |
| HALO - Halozyme Therapeutics Inc | SELL | -196 @ USD 64.47 | USD -12,636 | The ETF sold 196 shares of HALO on 2025-12-16. The shares were previously bought for an average price of USD 61.4961. The Halozyme Therapeutics Inc shares were sold for 4.8% higher than average price of previous purchases. This sale made a profit of USD 583 The average price that the ETF previously sold HALO share for is USD 59.5937 so the ETF has sold 196 shares on 2025-12-16 at a higher price than the previous selling average. |
| ARWR - Arrowhead Pharmaceuticals Inc | SELL | -232 @ USD 64.66 | USD -15,001 | The ETF sold 232 shares of ARWR on 2025-12-16. The shares were previously bought for an average price of USD 30.2525. The Arrowhead Pharmaceuticals Inc shares were sold for 113.7% higher than average price of previous purchases. This sale made a profit of USD 7,983 The average price that the ETF previously sold ARWR share for is USD 20.8756 so the ETF has sold 232 shares on 2025-12-16 at a higher price than the previous selling average. |
| RNA - Avidity Biosciences Inc | SELL | -217 @ USD 71.97 | USD -15,617 | The ETF sold 217 shares of RNA on 2025-12-16. The shares were previously bought for an average price of USD 46.9429. The Avidity Biosciences Inc shares were sold for 53.3% higher than average price of previous purchases. This sale made a profit of USD 5,431 The average price that the ETF previously sold RNA share for is USD 34.3171 so the ETF has sold 217 shares on 2025-12-16 at a higher price than the previous selling average. |
| BNTX - BioNTech SE | SELL | -170 @ USD 92.23 | USD -15,679 | The ETF sold 170 shares of BNTX on 2025-12-16. The shares were previously bought for an average price of USD 103.084. The BioNTech SE shares were sold for -10.5% lower than average price of previous purchases. This resulted in an overall loss of USD 1,845 The average price that the ETF previously sold BNTX share for is USD 104.22 which is higher than the selling price of USD 92.23 on 2025-12-16. |
| BMRN - Biomarin Pharmaceutical Inc | SELL | -323 @ USD 51.77 | USD -16,722 | The ETF sold 323 shares of BMRN on 2025-12-16. The shares were previously bought for an average price of USD 57.0929. The Biomarin Pharmaceutical Inc shares were sold for -9.3% lower than average price of previous purchases. This resulted in an overall loss of USD 1,719 The average price that the ETF previously sold BMRN share for is USD 61.6552 which is higher than the selling price of USD 51.77 on 2025-12-16. |
| JAZZ - Jazz Pharmaceuticals PLC | SELL | -102 @ USD 169.73 | USD -17,312 | The ETF sold 102 shares of JAZZ on 2025-12-16. The shares were previously bought for an average price of USD 135.407. The Jazz Pharmaceuticals PLC shares were sold for 25.3% higher than average price of previous purchases. This sale made a profit of USD 3,501 The average price that the ETF previously sold JAZZ share for is USD 124.325 so the ETF has sold 102 shares on 2025-12-16 at a higher price than the previous selling average. |
| EXEL - Exelixis Inc | SELL | -453 @ USD 41.6 | USD -18,845 | The ETF sold 453 shares of EXEL on 2025-12-16. The shares were previously bought for an average price of USD 41.6794. The Exelixis Inc shares were sold for -0.2% lower than average price of previous purchases. This resulted in an overall loss of USD 36 The average price that the ETF previously sold EXEL share for is USD 36.56 so the ETF has sold 453 shares on 2025-12-16 at a higher price than the previous selling average. |
| MRNA - Moderna Inc | SELL | -655 @ USD 29.89 | USD -19,578 | The ETF sold 655 shares of MRNA on 2025-12-16. The shares were previously bought for an average price of USD 28.1569. The Moderna Inc shares were sold for 6.2% higher than average price of previous purchases. This sale made a profit of USD 1,135 The average price that the ETF previously sold MRNA share for is USD 33.2644 which is higher than the selling price of USD 29.89 on 2025-12-16. |
| MDGL - Madrigal Pharmaceuticals Inc | SELL | -37 @ USD 554.57 | USD -20,519 | The ETF sold 37 shares of MDGL on 2025-12-16. The shares were previously bought for an average price of USD 411.281. The Madrigal Pharmaceuticals Inc shares were sold for 34.8% higher than average price of previous purchases. This sale made a profit of USD 5,302 The average price that the ETF previously sold MDGL share for is USD 343.967 so the ETF has sold 37 shares on 2025-12-16 at a higher price than the previous selling average. |
| GH - Guardant Health Inc | SELL | -209 @ USD 100 | USD -20,900 | The ETF sold 209 shares of GH on 2025-12-16. The shares were previously bought for an average price of USD 68.6525. The Guardant Health Inc shares were sold for 45.7% higher than average price of previous purchases. This sale made a profit of USD 6,552 The average price that the ETF previously sold GH share for is USD 43.1741 so the ETF has sold 209 shares on 2025-12-16 at a higher price than the previous selling average. |
| IONS - Ionis Pharmaceuticals Inc | SELL | -267 @ USD 78.37 | USD -20,925 | The ETF sold 267 shares of IONS on 2025-12-16. The shares were previously bought for an average price of USD 56.8592. The Ionis Pharmaceuticals Inc shares were sold for 37.8% higher than average price of previous purchases. This sale made a profit of USD 5,743 The average price that the ETF previously sold IONS share for is USD 41.6725 so the ETF has sold 267 shares on 2025-12-16 at a higher price than the previous selling average. |
| SNY - Sanofi ADR | SELL | -452 @ USD 47.44 | USD -21,443 | The ETF sold 452 shares of SNY on 2025-12-16. The shares were previously bought for an average price of USD 49.8689. The Sanofi ADR shares were sold for -4.9% lower than average price of previous purchases. This resulted in an overall loss of USD 1,098 The average price that the ETF previously sold SNY share for is USD 49.8507 which is higher than the selling price of USD 47.44 on 2025-12-16. |
| SMMT - Summit Therapeutics PLC | SELL | -1,250 @ USD 17.23 | USD -21,538 | The ETF sold 1250 shares of SMMT on 2025-12-16. The shares were previously bought for an average price of USD 20.4764. The Summit Therapeutics PLC shares were sold for -15.9% lower than average price of previous purchases. This resulted in an overall loss of USD 4,058 The average price that the ETF previously sold SMMT share for is USD 19.9122 which is higher than the selling price of USD 17.23 on 2025-12-16. |
| ASND - Ascendis Pharma AS | SELL | -102 @ USD 212.11 | USD -21,635 | The ETF sold 102 shares of ASND on 2025-12-16. The shares were previously bought for an average price of USD 186.345. The Ascendis Pharma AS shares were sold for 13.8% higher than average price of previous purchases. This sale made a profit of USD 2,628 The average price that the ETF previously sold ASND share for is USD 157.227 so the ETF has sold 102 shares on 2025-12-16 at a higher price than the previous selling average. |
| VTRS - Viatris Inc | SELL | -1,956 @ USD 11.46 | USD -22,416 | The ETF sold 1956 shares of VTRS on 2025-12-16. The shares were previously bought for an average price of USD 9.92002. The Viatris Inc shares were sold for 15.5% higher than average price of previous purchases. This sale made a profit of USD 3,012 The average price that the ETF previously sold VTRS share for is USD 10.4947 so the ETF has sold 1956 shares on 2025-12-16 at a higher price than the previous selling average. |
| BBIO - BridgeBio Pharma Inc | SELL | -322 @ USD 75.69 | USD -24,372 | The ETF sold 322 shares of BBIO on 2025-12-16. The shares were previously bought for an average price of USD 52.1831. The BridgeBio Pharma Inc shares were sold for 45.0% higher than average price of previous purchases. This sale made a profit of USD 7,569 The average price that the ETF previously sold BBIO share for is USD 35.355 so the ETF has sold 322 shares on 2025-12-16 at a higher price than the previous selling average. |
| RVMD - Revolution Medicines Inc | SELL | -315 @ USD 77.56 | USD -24,431 | The ETF sold 315 shares of RVMD on 2025-12-16. The shares were previously bought for an average price of USD 50.1446. The Revolution Medicines Inc shares were sold for 54.7% higher than average price of previous purchases. This sale made a profit of USD 8,636 The average price that the ETF previously sold RVMD share for is USD 43.1308 so the ETF has sold 315 shares on 2025-12-16 at a higher price than the previous selling average. |
| NBIX - Neurocrine Biosciences Inc | SELL | -167 @ USD 148.74 | USD -24,840 | The ETF sold 167 shares of NBIX on 2025-12-16. The shares were previously bought for an average price of USD 135.725. The Neurocrine Biosciences Inc shares were sold for 9.6% higher than average price of previous purchases. This sale made a profit of USD 2,174 The average price that the ETF previously sold NBIX share for is USD 125.866 so the ETF has sold 167 shares on 2025-12-16 at a higher price than the previous selling average. |
| MEDP - Medpace Holdings Inc | SELL | -47 @ USD 558.74 | USD -26,261 | The ETF sold 47 shares of MEDP on 2025-12-16. The shares were previously bought for an average price of USD 445.12. The Medpace Holdings Inc shares were sold for 25.5% higher than average price of previous purchases. This sale made a profit of USD 5,340 The average price that the ETF previously sold MEDP share for is USD 364.621 so the ETF has sold 47 shares on 2025-12-16 at a higher price than the previous selling average. |
| ROIV - Roivant Sciences Ltd | SELL | -1,145 @ USD 22.94 | USD -26,266 | The ETF sold 1145 shares of ROIV on 2025-12-16. The shares were previously bought for an average price of USD 15.2175. The Roivant Sciences Ltd shares were sold for 50.7% higher than average price of previous purchases. This sale made a profit of USD 8,842 The average price that the ETF previously sold ROIV share for is USD 11.8441 so the ETF has sold 1145 shares on 2025-12-16 at a higher price than the previous selling average. |
| RPRX - Royalty Pharma Plc | SELL | -727 @ USD 38.38 | USD -27,902 | The ETF sold 727 shares of RPRX on 2025-12-16. The shares were previously bought for an average price of USD 36.708. The Royalty Pharma Plc shares were sold for 4.6% higher than average price of previous purchases. This sale made a profit of USD 1,216 The average price that the ETF previously sold RPRX share for is USD 30.1912 so the ETF has sold 727 shares on 2025-12-16 at a higher price than the previous selling average. |
| INCY - Incyte Corporation | SELL | -328 @ USD 97.03 | USD -31,826 | The ETF sold 328 shares of INCY on 2025-12-16. The shares were previously bought for an average price of USD 81.6071. The Incyte Corporation shares were sold for 18.9% higher than average price of previous purchases. This sale made a profit of USD 5,059 The average price that the ETF previously sold INCY share for is USD 72.2311 so the ETF has sold 328 shares on 2025-12-16 at a higher price than the previous selling average. |
| ILMN - Illumina Inc | SELL | -258 @ USD 131.56 | USD -33,942 | The ETF sold 258 shares of ILMN on 2025-12-16. The shares were previously bought for an average price of USD 105.819. The Illumina Inc shares were sold for 24.3% higher than average price of previous purchases. This sale made a profit of USD 6,641 The average price that the ETF previously sold ILMN share for is USD 106.458 so the ETF has sold 258 shares on 2025-12-16 at a higher price than the previous selling average. |
| UTHR - United Therapeutics Corporation | SELL | -76 @ USD 500 | USD -38,000 | The ETF sold 76 shares of UTHR on 2025-12-16. The shares were previously bought for an average price of USD 380.392. The United Therapeutics Corporation shares were sold for 31.4% higher than average price of previous purchases. This sale made a profit of USD 9,090 The average price that the ETF previously sold UTHR share for is USD 351.62 so the ETF has sold 76 shares on 2025-12-16 at a higher price than the previous selling average. |
| BIIB - Biogen Inc | SELL | -246 @ USD 171.5 | USD -42,189 | The ETF sold 246 shares of BIIB on 2025-12-16. The shares were previously bought for an average price of USD 149.071. The Biogen Inc shares were sold for 15.0% higher than average price of previous purchases. This sale made a profit of USD 5,518 The average price that the ETF previously sold BIIB share for is USD 142.932 so the ETF has sold 246 shares on 2025-12-16 at a higher price than the previous selling average. |
| ARGX - argenx NV ADR | SELL | -51 @ USD 851.42 | USD -43,422 | The ETF sold 51 shares of ARGX on 2025-12-16. The shares were previously bought for an average price of USD 715.907. The argenx NV ADR shares were sold for 18.9% higher than average price of previous purchases. This sale made a profit of USD 6,911 The average price that the ETF previously sold ARGX share for is USD 635.823 so the ETF has sold 51 shares on 2025-12-16 at a higher price than the previous selling average. |
| INSM - Insmed Inc | SELL | -355 @ USD 200.67 | USD -71,238 | The ETF sold 355 shares of INSM on 2025-12-16. The shares were previously bought for an average price of USD 141.595. The Insmed Inc shares were sold for 41.7% higher than average price of previous purchases. This sale made a profit of USD 20,972 The average price that the ETF previously sold INSM share for is USD 86.974 so the ETF has sold 355 shares on 2025-12-16 at a higher price than the previous selling average. |
| AZN - AstraZeneca PLC | SELL | -870 @ USD 91.35 | USD -79,475 | The ETF sold 870 shares of AZN on 2025-12-16. The shares were previously bought for an average price of USD 78.7875. The AstraZeneca PLC shares were sold for 15.9% higher than average price of previous purchases. This sale made a profit of USD 10,929 The average price that the ETF previously sold AZN share for is USD 71.9385 so the ETF has sold 870 shares on 2025-12-16 at a higher price than the previous selling average. |
| ALNY - Alnylam Pharmaceuticals Inc | SELL | -218 @ USD 391.17 | USD -85,275 | The ETF sold 218 shares of ALNY on 2025-12-16. The shares were previously bought for an average price of USD 395.411. The Alnylam Pharmaceuticals Inc shares were sold for -1.1% lower than average price of previous purchases. This resulted in an overall loss of USD 925 The average price that the ETF previously sold ALNY share for is USD 279.688 so the ETF has sold 218 shares on 2025-12-16 at a higher price than the previous selling average. |
| REGN - Regeneron Pharmaceuticals Inc | SELL | -174 @ USD 746.36 | USD -129,867 | The ETF sold 174 shares of REGN on 2025-12-16. The shares were previously bought for an average price of USD 649.194. The Regeneron Pharmaceuticals Inc shares were sold for 15.0% higher than average price of previous purchases. This sale made a profit of USD 16,907 The average price that the ETF previously sold REGN share for is USD 623.224 so the ETF has sold 174 shares on 2025-12-16 at a higher price than the previous selling average. |
| GILD - Guild Esports Plc | SELL | -1,231 @ USD 118.78 | USD -146,218 | The ETF sold 1231 shares of GILD on 2025-12-16. The shares were previously bought for an average price of USD 115.871. The Guild Esports Plc shares were sold for 2.5% higher than average price of previous purchases. This sale made a profit of USD 3,581 The average price that the ETF previously sold GILD share for is USD 101.644 so the ETF has sold 1231 shares on 2025-12-16 at a higher price than the previous selling average. |
| AMGN - Amgen Inc | SELL | -483 @ USD 326.74 | USD -157,815 | The ETF sold 483 shares of AMGN on 2025-12-16. The shares were previously bought for an average price of USD 299.477. The Amgen Inc shares were sold for 9.1% higher than average price of previous purchases. This sale made a profit of USD 13,168 The average price that the ETF previously sold AMGN share for is USD 302.542 so the ETF has sold 483 shares on 2025-12-16 at a higher price than the previous selling average. |
| VRTX - Vertex Pharmaceuticals Inc | SELL | -356 @ USD 454.96 | USD -161,966 | The ETF sold 356 shares of VRTX on 2025-12-16. The shares were previously bought for an average price of USD 421.965. The Vertex Pharmaceuticals Inc shares were sold for 7.8% higher than average price of previous purchases. This sale made a profit of USD 11,746 The average price that the ETF previously sold VRTX share for is USD 469.711 which is higher than the selling price of USD 454.96 on 2025-12-16. |